Reading this on a mobile device? Try our optimized mobile version here: http://r.smartbrief.com/resp/enzDCfbwocfFbWxdmzuU

March 20, 2013
Sign upForwardArchiveAdvertiseRead more at SmartBrief.com
News for nuclear medicine and molecular imaging professionals
 
The news summaries appearing in SNMMI SmartBrief are based on original information from multiple internet sources and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The items below are not selected or reviewed by SNMMI prior to publication. Questions and comments may be directed to SmartBrief at snmmi@smartbrief.com.

  Top Story 
  ADVERTISEMENT  
Want big bucks for your company?
You want to sell your business, and you want to ensure that you get the best possible price. By taking 7 simple steps, you can dramatically improve your chances of attracting buyers and getting big bucks for your business. Read the article and learn the 7 steps.

  Clinical News & Research 
  • Study finds link between hypertension, Alzheimer's disease
    A study published in JAMA Neurology has found a link between hypertension and the development of Alzheimer's disease. Researchers used MRI and PET to measure levels of amyloid plaque, which is considered a risk factor for the disease. Patients with a genetic predisposition to Alzheimer's who were taking medication for hypertension had plaque levels that were no greater than other study subjects. The Inquisitr (3/19) LinkedInFacebookTwitterEmail this Story
  ADVERTISEMENT  
Sign up for SmartBrief on Social BusinessGet this daily email summary written by expert editors
As a valued SmartBrief reader, we are pleased to offer you a complimentary subscription to SmartBrief on Social Business. More than 90,000 of your peers count on this resource for essential news on the intersection of social media and business. Activate your free subscription today.

  Industry Report 
  • Gamma Medica closes sale of 2 business segments
    Gamma Medica has finalized its Chapter 11 bankruptcy protection proceedings through the sale of two business units: preclinical imaging and molecular breast imaging. The LumaGem MBI unit was bought by Imaging Acquisition, which is operated by Psilos Group Managers, while the preclinical business was sold to Northridge Trimodality Imaging. Gamma Medica acting CEO Jim Calandra said he believes Psilos will invest $10 million to $15 million with the MBI technology now in its hands. AuntMinnie.com (free registration) (3/19) LinkedInFacebookTwitterEmail this Story
  News from the Field 
  • Neuroscientist hopes virtual brain will unify research
    Neuroscientist Henry Markram is the brains behind Blue Brain, a web of nearly 10,000 virtual neurons designed to simulate living brain waves. Markram's next step, the Human Brain Project, will simulate an entire brain on a supercomputer. Critics say the project is poorly defined and premature, and will siphon scarce funds from other programs, but Markram sees his project as a unifying principle for other neuroscientists. The New York Times (tiered subscription model) (3/18) LinkedInFacebookTwitterEmail this Story
  • Manufacturing, regulatory complexities slow biosimilars
    Merck & Co., Teva Pharmaceutical Industries, Lonza and Samsung are among the companies that have scaled back plans to produce biosimilar versions of brand-name biologic drugs amid regulatory uncertainty, market volatility and high development and manufacturing costs. Bringing a biosimilar to market can cost up to $250 million by some estimates and can take six to nine years, compared with $1 million to $2 million and three years for a generic small-molecule drug. Genetic Engineering & Biotechnology News/Insight & Intelligence blog (3/18) LinkedInFacebookTwitterEmail this Story
  Health Policy 
  • Proposed budget hike would increase FDA oversight in China
    A Senate bill that aims to raise the FDA's fiscal 2013 budget to $2.5 billion has gained support from the Alliance for a Stronger FDA, which calls it "strongly favorable" to the agency. The measure, which includes the new user fees for medical devices, drugs and biologics, provides $10 million to allow the FDA to beef up its inspections in China, the agency said. In-PharmaTechnologist.com (3/18) LinkedInFacebookTwitterEmail this Story
  Advancing Health Care 
  ADVERTISEMENT  
  From SNMMI 
  • Upcoming SNMMI webinar: "AEs and the 1572: What Imaging Professionals Need to Know"
    During the course of a clinical trial, the research staff must follow certain guidelines to ensure that the protection of human subjects is always a top priority. Join Debra Messinger, CNMT, RT(R) — April 11 at 3:00 pm ET — as she describes the purpose and importance of the 1572 and discusses how the appropriate management of adverse events in a clinical trial is critical for its success. Register today. LinkedInFacebookTwitterEmail this Story
SNMMI  |  News  |  Meetings  |  Education  |  Publications  |  Membership

SNMMI on Facebook  |  SNMMI on LinkedIn  |  SNMMI on Twitter  |  SNMMI on YouTube

  SmartQuote 
Quality is not an act, it is a habit."
--Aristotle,
Greek philosopher


LinkedInFacebookTwitterEmail this Story

 
 
Subscriber Tools
   
Print friendly format  | Web version  | Search past news  | Archive  | Privacy policy

Advertise
Account Director:   Meryl Harold   (202) 407-7828
 
Read more at SmartBrief.com
 
 
 Recent SNMMI SmartBrief Issues:   Lead Editor:   Melissa Turner
     
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
 
 
© 1999-2013 SmartBrief, Inc.®  Legal Information